I am fortunate to have the opportunity to travel to multiple site initiation visits and trainings for clinical research studies each year. Meeting with the incredibly dedicated study teams is an invaluable experience as I am able to hear from the people who support the front line of clinical research. During a recent training, I sat down with a research coordinator who seemed to be stretched very thin. Noticing this, we took a step back to talk through her hesitations.
This week’s news that Takeda Pharmaceuticals inked a deal with Koneksa Health, a digital health startup that uses wearables and connected devices to gather patient data, reinforces the point that pharma companies have found a place for digital health tools in drug development. Koneksa Health CEO Chris Benko said he views the natural place for the use of these technologies in clinical studies either in early phases or as an exploratory addition in later phases in a phone interview with MedCity News.
There is an exciting paradigm shift happening in industry sponsored clinical trials, particularly for the patients contributing to research. Prior to joining Koneksa I worked for one of the highest enrolling clinical ophthalmology sites in the country, where over 25 studies were conducted at a time. I’ve experienced first-hand the significant burden placed on participants in clinical trials, with study visits lasting well over six hours.